News archive
Showing 692 results
October 2009
July 2009
-
Media Release
FDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
- Tekturna HCT combines the only approved direct renin inhibitor, Tekturna®, with widely used diuretic, hydrochlorothiazide, in a single pill- Data show combination of Tekturna and… -
Media Release
FDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
June 2009
-
Media Release
Video: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
- Phase III data show rapid and sustained remission in more than 90% of Ilaris-treated patients with cryopyrin-associated periodic syndrome (CAPS) - Ilaris is the first approved treatment for… -
Media Release
Video: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
April 2009
-
Media Release
Video: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
- Exforge HCT combines a proven calcium channel blocker, angiotensin receptor blocker and diuretic (amlodipine, valsartan, hydrochlorothiazide) in one pill - In a clinical trial, Exforge HCT… -
Media Release
Video: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
December 2008
-
Media Release
Video: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many… -
Media Release
Video: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
-
Media Release
RAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
- RAD001 combined with Herceptin and chemotherapy in two separate Phase I trials halted tumor growth in 77% and 62% of patients, respectively- Novartis to start Phase III clinical trial program to… -
Media Release
RAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial